Login
ASSEMBLY BIOSCIENCES, INC. logo

ASSEMBLY BIOSCIENCES, INC.

assemblybio.com

What Do They Do?

Develops investigational medicines for people with recurrent genital herpes, hepatitis B and hepatitis delta, as well as transplant-related herpesvirus infections.

How Do They Make Money?

Partners pay for licensed rights and research work: fees may be paid when a license transfers or as research is performed, while development milestone payments and royalties depend on milestones or partner sales.

FY2025 revenue

Who Are Their Customers?

Gilead licensed the herpes program and is a development and commercialization partner.

Do Revenues Turn Into Profits?

No. It lost $6.1M in FY2025.

Operating income, FY2025
−17% of revenue
▲ +73% (Loss) vs FY2024 (−$45.4M, −159%)
Net income, FY2025
−8% of revenue
▲ +85% (Loss) vs FY2024 (−$40.2M, −141%)
Free cash flow, FY2025
−57% of revenue
▲ +20% (Loss) vs FY2024 (−$51.1M, −179%)

How Are They Changing?

Growing. Revenue grew 11.6x in 4 years, from $6.3M in FY2021 to $72.3M in FY2025, about 84% a year.

Herpes program licensed to Gilead The older report said it was advancing a genital-herpes candidate toward clinical trials; the latest says Gilead licensed the herpes program and will take control of its development after the ongoing studies are complete.

Wider antiviral pipeline The older report centered its strategy on hepatitis B core inhibitors alongside herpes and other antiviral programs. The latest describes programs for herpes, hepatitis delta, hepatitis B and transplant-related herpesviruses.

Who Do They Compete With?

Competes with GlaxoSmithKline, Enanta Pharmaceuticals, Arbutus Biopharma, Vir Bio, Mirum Pharmaceuticals, Huahui Health, Aligos Therapeutics, Innovative Molecules, and AiCuris Anti-infective Cures

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support